Yves St Denis

Title: Yves St Denis: Innovator in CRF Receptor Antagonists

Introduction

Yves St Denis is a notable inventor based in Verona, Italy. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target corticotropin-releasing factor (CRF) receptors. With a total of two patents to his name, his work has implications for treating various disorders.

Latest Patents

Yves St Denis's latest patents include "Tri-and tetraaza-acenaphthylen derivatives as CRF receptor antagonists." This invention discloses CRF receptor antagonists that are useful in treating disorders characterized by hypersecretion of CRF in warm-blooded animals, such as stroke. The compounds have a specific structure, including stereoisomers, prodrugs, and pharmaceutically acceptable salts. Additionally, he has developed CRF receptor antagonists related to tricyclic pyrimidines, which also include stereoisomers and prodrugs. These compounds are designed for use in treating conditions mediated by CRF.

Career Highlights

Throughout his career, Yves St Denis has worked with prominent companies in the pharmaceutical industry. Notable among these are Neurocrine, Inc. and SmithKline Beecham Ltd. His work in these organizations has contributed to advancements in drug development and therapeutic applications.

Collaborations

Yves has collaborated with several professionals in his field, including Romano Di Fabio and Gabriella Gentile. These partnerships have likely enhanced the scope and impact of his research.

Conclusion

Yves St Denis is a distinguished inventor whose work on CRF receptor antagonists has the potential to transform treatment options for various disorders. His contributions to pharmacology and collaboration with industry leaders underscore his importance in the field.